NRC stock touches 52-week low at $10.31 amid sharp annual decline

National Research Corporation (NRC) stock has hit a 52-week low, trading at $10.31, despite maintaining strong fundamentals with a 60.2% gross margin and 62% return on equity. According to InvestingPro analysis, the company appears undervalued at current levels, while management demonstrates confidence through aggressive share buybacks. Over the past year, NRC has seen its stock price erode, culminating in a staggering 1-year change of -68.42%. This sharp decline has raised concerns among investors and analysts who are closely monitoring the company’s performance and potential strategies to recover from this low point. The current price level reflects investor sentiment and market conditions that have weighed heavily on the stock, signaling a critical moment for NRC’s management to address the underlying issues and restore confidence in the company’s growth prospects. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report that provides deep-dive analysis of NRC’s current position and future potential.

In other recent news, National Research Corporation has announced significant changes to its executive compensation structure, aligning it more closely with shareholder interests. These changes include a substantial stock grant and modified cash bonuses for certain officers, excluding the current and future CEOs. Helen L. Hrdy, the Chief Operating Officer, has been granted 100,000 shares of common stock, subject to specific conditions, and will receive a cash bonus based on the stock’s value. The company’s board has appointed Trent (NSE:TREN) Green as the incoming CEO, effective June 1, 2025, with these compensation adjustments reflecting the strategic direction under his leadership.

Additionally, National Research Corporation’s Board of Directors has approved a quarterly cash dividend of $0.12 per share, payable to shareholders of record as of March 28, 2025. This decision underscores the company’s commitment to returning value to shareholders and its confidence in its financial strength. In another development, UC Health has partnered with National Research Corporation to utilize its Market Insights and Community Insights solutions, aiming to enhance patient care through data-driven strategies. Helen Hrdy expressed enthusiasm about this partnership, anticipating that UC Health will benefit from the insights provided.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.